Genzyme Corporate Research Search Genzyme Websites
Information for Fabry Disease patients and their familiesFabry disease treatment information for health care professionals
Fabrazyme This website is intended for use in the United States. Please visit the Genzyme website for your country or region.
Patients and Families
About Fabry Disease
About Fabrazyme
Treatment
Symptom Management
What to Expect from ERT
Continuing Treatment
Infusion Scheduler
Support and Resources
Product Information
Genzyme Fabrazyme

Continuing Treatment

Fabrazyme® (agalsidase beta) enzyme replacement therapy may be a lifelong part of your treatment for Fabry disease.

For people with Fabry disease, regular treatment every two weeks with the replacement enzyme is essential for maintaining reduced GL-3 levels.

In addition, talk to your doctor before you stop taking any other medications. While your doctor may determine that you need less of some medications, others may still be necessary.

Plan Ahead for Moves and Travel

Going on vacation? To college? Moving? It's important to continue treatment with Fabrazyme. Plan ahead so you don't miss infusions. Talk to your doctor about arranging for treatment at your destination.

Infusion Scheduler

You may find it helpful to keep track of when your Fabrazyme infusions are scheduled so that you don’t miss treatment. Use the Infusion Scheduler tool to create a printable schedule that you can fill in.

Notify your Employer of Scheduled Treatment

Since Fabrazyme may be a long-term commitment to treatment for your condition, infusions are likely to be a regularly-scheduled event in your life. Infusions may need to occur during work hours. You may wish to send a letter to your employer to help them better understand your condition and need for regular treatment.

Here is an example letter that can help you explain your medical condition to your employer. This can be personalized using Microsoft® Word. Wherever you see notes in parentheses, you can fill in the information that pertains to your situation.

What Happens if You Miss an Infusion?

If you miss an infusion, talk to your doctor about rescheduling your appointment. Regular infusions every two weeks are very important since your body does not produce enough of the alpha-GAL enzyme necessary to control the build-up of GL-3.

Monitoring Progress

Just as Fabry disease affects different people differently, responses to treatment will vary from person to person, as well. Your physician will likely want to see you regularly to check how you are responding to Fabrazyme treatment and to assess your overall health. Your physician may also have recommendations about nutritional changes in your diet or changes in exercise or activity levels.

You can play a role in monitoring your own progress, as well. Complete the Talk to Your Doc Report (PDF) and share it with your physician. Open communication with your team of health care professionals is important so you can receive appropriate care.

Annual Comprehensive Visits

In addition to regular visits to your doctor, it is recommended that most people with Fabry disease have a comprehensive medical evaluation every year. These annual visits are important because they allow you to be seen by a variety of specialists, who can monitor how Fabry disease and treatment are affecting different parts of your body.

Contact Genzyme Medical Information at 800-745-4447 or 617-768-9000, option 2 for more information on centers that have experience treating patients with Fabry disease.


Important Safety Information

Fabrazyme (agalsidase beta) is indicated for use in patients with Fabry disease.  Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types. The reduction of GL-3 inclusions suggests that Fabrazyme may ameliorate disease expression; however, the relationship of GL-3 inclusion reduction to specific clinical manifestations of Fabry disease has not been established.

The most serious and most common adverse reactions reported with Fabrazyme are infusion reactions.  Serious and/or frequently occurring related adverse reactions consisted of one or more of the following events: chills, pyrexia, feeling hot or cold, dyspnea, nausea, flushing, headache, vomiting, paresthesia, fatigue, pruritus, pain in extremity, hypertension, chest pain, throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion, diarrhea, edema peripheral, myalgia, back pain, pallor, bradycardia, urticaria, hypotension, face edema, rash, and somnolence. The occurrence of somnolence can be attributed to clinical trial specified pre-treatment with antihistamines. 
 
Other reported serious adverse events included stroke, pain, ataxia, bradycardia, cardiac arrhythmia, cardiac arrest, decreased cardiac output, vertigo, hypoacousia, and nephrotic syndrome.  These adverse events also occur as manifestations of Fabry disease; an alteration in frequency or severity cannot be determined from the small numbers of patients studied.

Infusion reactions occurred in many patients treated with Fabrazyme and some of the reactions were severe.  Patients should be given antipyretics prior to infusion.  Infusion reactions occurred in some patients after receiving pretreatment with antipyretics, antihistamines, and oral steroids.  Infusion reactions declined in frequency with continued use of Fabrazyme.  However, infusion reactions may still occur despite extended duration of Fabrazyme treatment.  Because of the potential for severe infusion reactions, appropriate medical support measures should be readily available when Fabrazyme is administered. 

Patients with compromised cardiac function should be monitored closely if the decision is made to administer Fabrazyme.

Most patients develop IgG antibodies to Fabrazyme.  A few patients developed IgE or skin test reactivity specific to Fabrazyme.  Physicians should consider testing for IgE in patients who experienced suspected allergic reactions and consider the risks and benefits of continued treatment in patients with anti- Fabrazyme IgE.   Patients with Fabrazyme- specific IgE antibody have been treated using a rechallenge protocol.  Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

The safety and efficacy in patients younger than 8 years of age have not been evaluated.  IgE immunologic responses in pediatric patients may differ from those in adults, as IgG seroconversion was associated with prolonged half-life concentrations of Fabrazyme, which is rarely observed in adult patients.

Fabrazyme is available by prescription only. Side effects should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn more, please see the full prescribing information (PDF) or contact Genzyme at 1-800-745-4447.
 
Keyword: 
Search In: 
Resources

Insurance and Reimbursement
Information Request
Ask Us
Learn About the Fabry Registry
Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142
617 768 9000
800 745 4447
Contact Us
 
This website is intended for use in the United States. Please visit the Genzyme website for your country or region.



Terms and Conditions of Use | Privacy Policy | © 2003-2008 Genzyme Corporation. All rights reserved. |  Fabr/US/P133/02/07 |  Site Map
Genzyme Therapeutics